GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists have taken the medical world by storm, largely due to their remarkable ability to promote weight loss. Drugs like semaglutide, tirzepatide, and retatrutide have become widely popular, but their benefits extend far beyond shedding pounds. From transforming diabetes management to protecting hearts and brains, these peptide-based therapies are rewriting the script for chronic disease care in 2025. In this blog, we dive into the lesser-known benefits of GLP-1/GIP agonists, backed by case studies, and explore how telehealth makes these treatments accessible to all.

What Are GLP-1/GIP Agonists?

GLP-1 and GIP are gut hormones that regulate blood sugar, appetite, and metabolism. GLP-1/GIP agonists mimic these hormones, stimulating insulin release, slowing gastric emptying, and reducing appetite. Originally developed for type 2 diabetes (T2D), their weight loss effects grabbed headlines, but their broader benefits are equally compelling. These drugs are typically injected, though oral formulations like JNJ-2113 are emerging [New England Journal of Medicine, 2024]. Let’s explore their impact beyond the scale.

Key Benefits Beyond Weight Loss

1. Superior Type 2 Diabetes Management

GLP-1/GIP agonists are game-changers for T2D, improving glycemic control without the hypoglycemia risk of older drugs like sulfonylureas.

• How It Works: They enhance insulin secretion in a glucose-dependent manner, suppress glucagon (which raises blood sugar), and improve insulin sensitivity.
• Case Study: In the SURPASS-2 trial (2021), tirzepatide (5–15 mg weekly) reduced HbA1c by 2.3% in T2D patients over 40 weeks, compared to 1.9% with semaglutide (1 mg). A 52-year-old woman with a baseline HbA1c of 8.7% achieved 6.4% on tirzepatide, avoiding insulin therapy and reporting more energy [The Lancet, 2021].
• Why It Matters: Lower HbA1c reduces complications like neuropathy and retinopathy. Patients also report fewer dietary restrictions, improving quality of life.

2. Cardiovascular Protection

Heart disease is a leading cause of death, especially for those with T2D or obesity. GLP-1/GIP agonists reduce cardiovascular (CV) events, offering a lifeline for at-risk patients.

• How It Works: They lower blood pressure, improve lipid profiles (e.g., reducing LDL cholesterol), and reduce inflammation, protecting arteries.
• Case Study: The STEP-HFpEF trial (2023) studied semaglutide (2.4 mg) in obese patients with heart failure with preserved ejection fraction (HFpEF). A 63-year-old man with a BMI of 38 and recurrent hospitalizations saw a 20% improvement in exercise capacity and a 15 mmHg drop in systolic blood pressure after 52 weeks, avoiding further CV events [New England Journal of Medicine, 2023].
• Why It Matters: The FDA approved semaglutide in 2021 for CV risk reduction in T2D patients, based on the SUSTAIN-6 trial, which showed a 26% reduction in major CV events. Tirzepatide’s SURPASS-CVOT trial (ongoing, 2025) is expected to confirm similar benefits [Signal Transduction and Targeted Therapy, 2025].

3. Neuroprotection and Cognitive Health

Emerging research suggests GLP-1/GIP agonists may protect against neurodegenerative diseases like Alzheimer’s and Parkinson’s, sparking excitement in 2025.

• How It Works: They cross the blood-brain barrier, reducing neuroinflammation, enhancing insulin signaling in the brain, and promoting neuronal survival.
• Case Study: A 2024 phase 2 trial at University College London tested liraglutide (1.8 mg daily) in early Alzheimer’s patients. A 70-year-old woman with mild cognitive impairment showed a 18% slower decline in cognitive scores (ADAS-Cog) and reduced brain amyloid plaque buildup after 12 months, compared to placebo [Alzheimer’s Research & Therapy, 2024].
• Why It Matters: With no cure for Alzheimer’s, GLP-1 agonists offer hope for slowing progression. Trials like EVOKE Plus (semaglutide) are ongoing, with results expected in 2026 [X post by @NeuroPeptides, 2025].

4. Kidney Function Preservation

Chronic kidney disease (CKD) is a common complication of T2D and obesity. GLP-1/GIP agonists slow CKD progression, preserving kidney function.

• How It Works: They reduce glomerular pressure, inflammation, and proteinuria (excess protein in urine), protecting kidneys.
• Case Study: In the FLOW trial (2024), semaglutide (1 mg) reduced kidney failure risk by 24% in T2D patients with CKD. A 58-year-old man with stage 3 CKD (eGFR 45 mL/min) improved to eGFR 52 mL/min after 48 weeks, delaying dialysis [The Lancet Diabetes & Endocrinology, 2024].
• Why It Matters: CKD affects 1 in 7 adults globally. GLP-1 agonists could reduce dialysis dependence, easing healthcare burdens.

5. Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement

NAFLD, linked to obesity and T2D, can progress to severe liver damage. GLP-1/GIP agonists reduce liver fat, offering a non-invasive treatment.

• How It Works: They decrease hepatic fat accumulation and inflammation, partly via weight loss and improved insulin sensitivity.
• Case Study: A 2023 phase 2 trial of tirzepatide (10–15 mg) in NAFLD patients showed a 55% reduction in liver fat content (measured by MRI-PDFF). A 45-year-old woman with a liver fat fraction of 20% reduced it to 8%, normalizing liver enzymes [Hepatology, 2023].
• Why It Matters: No FDA-approved NAFLD drugs exist, making GLP-1/GIP agonists a promising option.

6. Autoimmune Disease Symptom Amelioration

Autoimmune diseases, such as rheumatoid arthritis and psoriasis, involve chronic inflammation that can severely impact quality of life. Emerging evidence suggests GLP-1/GIP agonists may reduce inflammation and improve symptoms in some autoimmune conditions.

• How It Works: GLP-1/GIP agonists modulate immune responses by reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6) and enhancing anti-inflammatory pathways, partly through improved metabolic health and reduced adipose tissue inflammation.
• Case Study: In a 2024 phase 2b trial (PROPAGATE-1), JNJ-2113, an oral dual GLP-1/GIP agonist, was tested in patients with moderate-to-severe psoriasis. A 42-year-old man with a Psoriasis Area and Severity Index (PASI) score of 18 achieved a 75% reduction (PASI-75) after 16 weeks of 100 mg daily dosing, alongside improved joint pain from psoriatic arthritis, with no significant side effects [New England Journal of Medicine, 2024].
• Why It Matters: Current autoimmune treatments, like biologics, can be costly and increase infection risk. GLP-1/GIP agonists offer a novel, potentially safer adjunct therapy, especially for patients with coexisting metabolic issues like obesity or T2D.

Challenges and Future Directions

GLP-1/GIP agonists aren’t perfect. Side effects like nausea (affecting ~20% of users) or rare risks like pancreatitis require monitoring. Emerging oral formulations (e.g., JNJ-2113) could replace injections, boosting adherence [Frontiers in Pharmacology, 2025].

Future research is exciting:

• Triple Agonists: Retatrutide (GLP-1/GIP/glucagon) is in phase 3 trials, showing HbA1c reductions of 2.8% and CV benefits [Signal Transduction and Targeted Therapy, 2025].
• Neurodegeneration: Phase 3 trials for semaglutide in Parkinson’s are launching in 2025 [X post by @BrainHealthNow, 2025].
• Combination Therapies: PDCs combining GLP-1 agonists with other peptides are being explored for enhanced efficacy [PolyPeptide, 2024].

Why This Matters for You

GLP-1/GIP agonists are more than weight loss drugs—they’re transforming lives by controlling diabetes, protecting hearts, preserving kidneys, and potentially safeguarding brains. Whether you’re managing T2D, worried about heart health, or curious about cognitive benefits, these therapies offer hope. Telehealth makes it easier than ever to explore them, with lab tests and prescriptions just a click away.

Ready to learn more? Head over to the “Getting Started” tab and scroll down to “Interested in Weight loss or Peptide Only” to schedule a consult with us!

---

Source List

1. Alzheimer’s Research & Therapy. (2024). Liraglutide in early Alzheimer’s disease: a randomized controlled trial. Alzheimer’s Research & Therapy, 16(1), 45–56. [Source for Section 3: Neuroprotection and Cognitive Health].
2. Frontiers in Endocrinology. (2024). Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology, 15, 1289–1301. [Source for Section 6: Autoimmune Disease Symptom Amelioration].
3. Frontiers in Pharmacology. (2025). Advances in oral GLP-1/GIP receptor agonists. Frontiers in Pharmacology, 16, 1023–1035. [Source for Sections 1–5: General advancements in GLP-1/GIP therapies].
4. Hepatology. (2023). Tirzepatide reduces liver fat content in NAFLD: a phase 2 trial. Hepatology, 77(4), 1123–1134. [Source for Section 5: Non-Alcoholic Fatty Liver Disease Improvement].
5. Journal of Telemedicine and Telecare. (2024). Telehealth improves HbA1c control in rural T2D patients using GLP-1 agonists. Journal of Telemedicine and Telecare, 30(5), 789–798. [Source for Sections 1–5: Accessibility and Inclusivity].
6. New England Journal of Medicine. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(25), 2221–2232. [Source for Section 2: Cardiovascular Protection].
7. New England Journal of Medicine. (2024). Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor Agonists. New England Journal of Medicine, 391(15), 1345–1356. [Source for Sections 1, 6: Type 2 Diabetes Management and Autoimmune Disease Symptom Amelioration].
8. PolyPeptide. (2024). Innovations in peptide-drug conjugates for metabolic diseases. PolyPeptide White Paper Series, 2024(3), 12–18. [Source for Sections 1–5: Future Directions].
9. PubMed Central (PMC). (2024). Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. PMC Articles, PMC10876543. [Source for Section 6: Autoimmune Disease Symptom Amelioration].
10. Signal Transduction and Targeted Therapy. (2024). Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 9, 456–468. [Source for Section 6: Autoimmune Disease Symptom Amelioration].
11. Signal Transduction and Targeted Therapy. (2025). Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 10(1), 123–135. [Source for Sections 1–5: Type 2 Diabetes Management, Cardiovascular Protection, and Future Directions].
12. The Lancet. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). The Lancet, 398(10295), 39–50. [Source for Section 1: Type 2 Diabetes Management].
13. The Lancet Diabetes & Endocrinology. (2024). Semaglutide and kidney outcomes in type 2 diabetes: FLOW trial. The Lancet Diabetes & Endocrinology, 12(6), 401–412. [Source for Section 4: Kidney Function Preservation].
14. X Post by @BrainHealthNow. (2025, January 15). Semaglutide trials for Parkinson’s launching in 2025. Retrieved from X platform. [Source for Sections 3, 5: Neuroprotection and Future Directions].
15. X Post by @HealthTech2025. (2025, February 10). Generic semaglutide expected in 2026, improving access. Retrieved from X platform. [Source for Sections 1–5: Accessibility and Inclusivity].
16. X Post by @NeuroPeptides. (2025, March 5). EVOKE Plus trial for semaglutide in Alzheimer’s: results due 2026. Retrieved from X platform. [Source for Section 3: Neuroprotection and Cognitive Health].

---